Target
Cytochrome P450 2C9
Ligand
BDBM50314816
Substrate
n/a
Meas. Tech.
ChEMBL_627242 (CHEMBL1110811)
IC50
3700±n/a nM
Citation
 Li, JKennedy, LJShi, YTao, SYe, XYChen, SYWang, YHernández, ASWang, WDevasthale, PVChen, SLai, ZZhang, HWu, SSmirk, RABolton, SARyono, DEZhang, HLim, NKChen, BCLocke, KTO'Malley, KMZhang, LSrivastava, RAMiao, BMeyers, DSMonshizadegan, HSearch, DGrimm, DZhang, RHarrity, TKunselman, LKCap, MKadiyala, PHosagrahara, VZhang, LXu, CLi, YXMuckelbauer, JKChang, CAn, YKrystek, SRBlanar, MAZahler, RMukherjee, RCheng, PTTino, JA Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). J Med Chem 53:2854-64 (2010) [PubMed]  Article 
Target
Name:
Cytochrome P450 2C9
Synonyms:
(R)-limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | CP2C9_HUMAN | CYP2C10 | CYP2C9 | CYPIIC9 | Cytochrome P450 2C9 (CYP2C9 ) | Cytochrome P450 2C9 (CYP2C9) | P-450MP | P450 MP-4/MP-8 | P450 PB-1 | S-mephenytoin 4-hydroxylase
Type:
Enzyme
Mol. Mass.:
55636.33
Organism:
Homo sapiens (Human)
Description:
P11712
Residue:
490
Sequence:
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV
  
Inhibitor
Name:
BDBM50314816
Synonyms:
2-((3-((2-(4-chlorophenyl)-4-methylthiazol-5-yl)methoxy)benzyl)(ptolyloxycarbonyl)amino)acetic acid | CHEMBL1090212
Type:
Small organic molecule
Emp. Form.:
C28H25ClN2O5S
Mol. Mass.:
537.027
SMILES:
Cc1nc(sc1COc1cccc(CN(CC(O)=O)C(=O)Oc2ccc(C)cc2)c1)-c1ccc(Cl)cc1
Structure:
Search PDB for entries with ligand similarity: